Expands institutional footprint with potential penetration of more than ~ 60% of the U.S. market, while expanding reach across EMS providers and rehabilitation centers COMMACK, NY, March 11, 2026 ...

Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025 In post hoc analysis of the pivotal RESILIENT study, TONMYA produced rapid pain relief as early as Day 2 ...

Expands institutional footprint with potential penetration of more than ~ 60% of the U.S. market, while expanding reach across EMS providers and rehabilitation centers U.S. naloxone market totals $141 ...

All three patients enrolled in study have been cured, confirming high cure rate of tafenoquine in immunosuppressed patients, as reported by Yale in a 2024 publicationCompany calls for existing ...

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 ...

Move comes 2 years after controversial exit of brand-name product ...

The FDA approved a vaccine for mumps nearly 60 years ago, so why are some areas of the United States experiencing outbreaks ...

TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025 Treatment with TONMYA provided statistically significant pain ...

Switzerland, March 10, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced its financial and operational results for the full ...

TerSera Therapeutics LLC today announced that it has completed the previously announced sale of its Infusion Specialty Therapies Business Unit (IST), including two specialty medications, Prialt® ...

Noticing a receding hairline? You’re not alone — and thanks to years of research, effective treatments are within reach. Male ...

Significantly more patients treated with once-daily, oral Sotyktu achieved an ACR20 response compared with placebo at ...